The Company

Symetis is the leading European developer of innovative, minimally invasive heart valve replacement devices. The company’s products, ACURATE TA™ and ACURATE neo™ and their delivery systems, based on proprietary design and delivery technologies, are marketed and sold in key markets in Europe and in other markets, and are well positioned to target the constantly growing TAVI market. Symetis is financed by a syndicate of blue chip venture capital firms. The company’s headquarters are in Ecublens (Lausanne), Switzerland; its manufacturing sites are in Ecublens and Belo Horizonte, Brazil.